Welcome to our dedicated page for Incyte news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte stock.
Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.
Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.
Incyte (INCY) has announced equity inducement awards for its new Executive Vice President and Head of U.S. Oncology, Mohamed Issa. The awards, approved by the company's compensation committee under Nasdaq Listing Rule 5635(c)(4), include two separate RSU grants:
1. An initial award of 48,671 restricted stock units (RSUs) with a grant and vesting date of January 6, 2025
2. A subsequent award of 27,812 RSUs to be granted on June 30, 2025
Both awards will vest over four years, with 25% vesting annually, contingent on Dr. Issa's continued employment with the company.
Incyte (Nasdaq: INCY) announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.
The event will be held on Monday, January 13, 2025, at 10:30 am (PST). The presentation will be webcast live and accessible through Investor.Incyte.com. A replay of the webcast will be available for 30 days.
Incyte (INCY) announced positive results from the Phase 3 inMIND trial of tafasitamab (Monjuvi®) for relapsed or refractory follicular lymphoma. The study met its primary endpoint, showing significantly improved progression-free survival (PFS) of 22.4 months compared to 13.9 months in the control arm, representing a 57% reduction in risk.
The trial demonstrated improvements across secondary endpoints, including complete response (49.4% vs 39.8%), overall response rate (83.5% vs 72.4%), and duration of response (21.2 vs 13.6 months). The treatment was generally well-tolerated, with common side effects including neutropenia (48.5%), diarrhea (37.6%), and COVID-19 (31.4%).
Based on these results, Incyte plans to file a supplemental Biologics License Application for tafasitamab in FL by year-end 2024.
Incyte (INCY) announced positive results from Phase 3 POD1UM-304 trial evaluating retifanlimab (Zynyz®) combined with platinum-based chemotherapy in previously untreated metastatic non-small cell lung cancer (NSCLC) patients. The trial met its primary endpoint with significant improvement in overall survival of 18.1 months versus 13.4 months for chemotherapy alone.
Secondary endpoints were also met, showing 2-month improvement in progression-free survival (7.7 vs 5.5 months), higher overall response rate (52% vs 39%), and longer duration of response (12.7 vs 6.1 months). The treatment was generally well-tolerated with common side effects including anemia (62.7%), decreased appetite (22.6%), and decreased neutrophil count (22.1%). The company plans to submit a supplemental Biologics License Application in 2025.
Incyte (INCY) has announced the granting of restricted stock unit awards (RSUs) to 15 new employees, totaling 7,259 shares of common stock. The grants were made under the company's 2024 Inducement Stock Incentive Plan, with both grant date and vesting commencement date set for December 2, 2024. The compensation committee approved these awards as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four equal annual installments of 25% each, contingent upon continued employment with the company.
Incyte (Nasdaq: INCY) has updated its presentation schedule for Citi's 2024 Global Healthcare Conference. The company will now present on Tuesday, December 3, 2024, at 8:00 a.m. Interested parties can access the live webcast through Investor.Incyte.com, and a replay will remain available for 30 days following the presentation.
Incyte (INCY) announced its upcoming presentations at the 2024 ASH Annual Meeting, featuring twenty presentations across seven medicines. The highlight is a late-breaking Phase 3 inMIND study presentation on tafasitamab in follicular lymphoma. The presentations include data from various treatments including axatilimab, INCB057643, ruxolitinib, ponatinib, and others, covering areas such as myeloproliferative neoplasms, graft-versus-host disease, and lymphomas.
The company will host a virtual analyst and investor event on December 12, 2024, to discuss key data presentations, particularly focusing on the inMIND study results and BET inhibitor program.
Incyte (INCY) announced the pause of enrollment in its Phase 2 study of MRGPRX2 (INCB000262) in chronic spontaneous urticaria due to preclinical toxicology findings. The company will collaborate with the FDA to determine next steps. While enrollment in other INCB000262 proof-of-concept studies is complete, the data will inform future development decisions and guide potential back-up molecule development. Additionally, Phase 2 study results for MRGPRX4 (INCB000547) in cholestatic pruritus were unfavorable, leading to discontinuation of its development.
Incyte (Nasdaq: INCY) has announced its upcoming participation at Citi's 2024 Global Healthcare Conference. The presentation is scheduled for Tuesday, December 3, 2024, at 3:15 p.m. in Miami. Investors and interested parties can access the live webcast through Investor.Incyte.com, and a replay will remain available for 30 days following the presentation.
Incyte (Nasdaq:INCY) announced the granting of restricted stock unit awards (RSUs) and stock options to 27 new employees. The awards include 33,003 RSU shares and options to purchase 15,812 shares at $76.13 per share. The grants were made under the 2024 Inducement Stock Incentive Plan, effective November 1, 2024. RSUs vest 25% annually over four years, while stock options vest 25% after one year, with remaining portions vesting monthly over 36 months. Both are subject to continued employment.